Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Management of Chronic Kidney Disease Stages 1–3

Slide: 15 of 29

Clinical Bottom Line: Risk for ESRD in Patients With CKD Stages 1–3 Treated With Other Interventions

There was low-strength evidence that the risk for end-stage renal disease (ESRD) was similar for the remaining comparisons reviewed in the comparative effectiveness review, which included a beta-blocker, a calcium channel blocker (CCB), or a statin versus a control or placebo; a CCB versus a beta-blocker; strict versus standard blood pressure control; or a low-protein versus a usual diet or a carbohydrate-restricted, low-iron-available, polyphenol-enriched diet.